Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents)
  4. Volume 24, Issue 2
  5. Article
Volume 24, Issue 2
  • ISSN: 1871-5230
  • E-ISSN: 1875-614X

Abstract

Aims

This study aimed at the synthesis of several spiro[benzofuran-3,3'-pyrroles] derivatives by a three-component reaction conducted by mixing DMAD, -bridgehead heterocycles, and benzofuran-2,3-diones in dichloromethane at room temperature for 24 h. Moreover, evaluation of their cytotoxicity affinities against FMS-like tyrosine kinase 3 was carried out.

Objectives

The objective of this study was to use a one-pot, three-component reaction to synthesize a novel set of spiro[benzofuran-3,3'-pyrroles] derivatives.

Methods

A novel set of spiro[benzofuran-3,3'-pyrroles] (()a-e) was synthesized by a one-pot three-component reaction involving dimethyl acetylenedicarboxylate, -bridgehead heterocycles and benzofuran-2,3-diones in dichloromethane at room temperature for 24 h. The compounds were analyzed using NMR 1H, 13C, 2D-NMR (COSY, HMQC, HMBC), and HRMS. Docking simulations were conducted to elucidate the anticancer activity of synthesized compounds on FLT3 protein, with Gilteritinib as a reference for comparison.

Results

This study demonstrated the successful design, synthesis, and biological evaluation of spiro[benzofuran-3,3'-pyrroles] derivatives as FLT3 inhibitors for AML treatment. The synthesized compounds demonstrated promising binding affinities and significant inhibitory activity against FLT3 kinase. The inhibitors (11a, 11b, 11c, 12d, and 12e) exhibited excellent selectivity profiles against FLT3. Particularly, compound showed strong binding affinity and potent inhibitory activity (IC = 2.5 μM).

Conclusion

Fifteen new synthetic spiro[benzofuran-3,3'-pyrroles] were prepared, characterized, and evaluated for cytotoxicity affinities against FMS-like tyrosine kinase 3. Compound showed strong binding affinity and potent inhibitory activity (IC = 2.5 μM), making it a promising candidate for further development as a therapeutic option for AML treatment. These findings lay the groundwork for further optimization and development of spiro[benzofuran-3,3'-pyrroles] derivatives as potential therapeutics for AML treatment. Further studies are needed to explore their efficacy and safety profiles in preclinical and clinical settings.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/aiaamc/10.2174/0118715230343474241009112335
2024-12-06
2025-06-28

  • From This Site

    /content/journals/aiaamc/10.2174/0118715230343474241009112335
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ZhaoJ.C. AgarwalS. AhmadH. AminK. BewersdorfJ.P. ZeidanA.M. A review of FLT3 inhibitors in acute myeloid leukemia.Blood Rev.20225210090510.1016/j.blre.2021.10090534774343
     [Google Scholar]
  2. EzelarabH.A.A. AliT.F.S. AbbasS.H. HassanH.A. BeshrE.A.M. Indole-based FLT3 inhibitors and related scaffolds as potential therapeutic agents for acute myeloid leukemia.BMC Chem.20231717310.1186/s13065‑023‑00981‑837438819
     [Google Scholar]
  3. NingombamA. VermaD. KumarR. SinghJ. AliM.S. PandeyA.K. SinghI. BakhshiS. SharmaA. PushpamD. PalanichamyJ.K. TanwarP. SinghA.R. ChopraA. Prognostic relevance of NPM1, CEBPA, and FLT3 mutations in cytogenetically normal adult AML patients.Am. J. Blood Res.2023131284336937459
     [Google Scholar]
  4. AlserihiR. AhmadH. AlkhatabiH. Analysis of NPM1 and FLT3 Mutations in Patients with Acute Myeloid Leukemia in Jeddah, Saudi Arabia: A Pilot Study.Int. J. Biom.2023131738310.21103/Article13(1)_OA9
     [Google Scholar]
  5. TsengS. LeeM.E. LinP.C. A review of childhood acute myeloid leukemia: Diagnosis and novel treatment.Pharmaceuticals (Basel)20231611161410.3390/ph1611161438004478
     [Google Scholar]
  6. GeS.S. QiuQ.C. DaiH.P. ShenX.D. WuT.M. DuJ.H. WanC.L. ShenH.J. WuD.P. XueS.L. LiuS.B. Mutation spectrum of FLT3 and significance of non‐canonical FLT3 mutations in haematological malignancy.Br. J. Haematol.2023202353954910.1111/bjh.1887737246158
     [Google Scholar]
  7. KurzerJ.H. WeinbergO.K. Updates in molecular genetics of acute myeloid leukemia.Semin. Diagn. Pathol.202340314015110.1053/j.semdp.2023.04.00237059636
     [Google Scholar]
  8. KiyoiH. KawashimaN. IshikawaY. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development.Cancer Sci.2020111231232210.1111/cas.1427431821677
     [Google Scholar]
  9. GeS.S. LiuS.B. XueS.L. Developments and challenges of FLT3 inhibitors in acute myeloid leukemia.Front. Oncol.20221299643810.3389/fonc.2022.99643836185253
     [Google Scholar]
  10. GuiH.Z. MengZ. XiaoZ.S. YangZ.R. WeiY. ShiM. Stereo‐ and regioselective construction of spirooxindoles having continuous spiral rings via asymmetric [3+2] cyclization of 3‐isothiocyanato oxindoles with thioaurone derivatives.Eur. J. Org. Chem.20202020426614662210.1002/ejoc.202001146
     [Google Scholar]
  11. MhiriC. BoudrigaS. AskriM. KnorrM. SriramD. YogeeswariP. NanaF. GolzC. StrohmannC. Design of novel dispirooxindolopyrrolidine and dispirooxindolopyrrolothiazole derivatives as potential antitubercular agents.Bioorg. Med. Chem. Lett.201525194308431310.1016/j.bmcl.2015.07.06926271585
     [Google Scholar]
  12. Al-MahadeenM.M. JaberA.M. ZahraJ.A. El-AbadelahM.M. AlshaerW. TahaM.O. Synthesis of novel benzothieno-[3,2′-f][1,3] oxazepines and their isomeric 2-oxo-2H-spiro[benzothiophene-3,3′-pyrrolines] via 1,4-dipolar cycloaddition reaction and their evaluation as cytotoxic anticancer leads.Med. Chem. Res.202433691892910.1007/s00044‑024‑03229‑9
     [Google Scholar]
  13. ChenH. LiuH. ZhaoS.H. ChengS-B. XuX-Y. YuanW-C. ZhangX-M. Enantioselective arylation of 3-carboxamide oxindoles with quinone monoimines and synthesis of chiral spirooxindole-benzofuranones.Synlett20193091067107210.1055/s‑0037‑1611782
     [Google Scholar]
  14. JaberA.M. ZahraJ.A. El-AbadelahM.M. Al-MahadeenM.M. SabriS.S. KasabriV. HaddadinR.N. Evaluation of spirooxindole-3,3′-pyrrolines-incorporating isoquinoline motif as antitumor, anti-inflammatory, antibacterial, antifungal, and antioxidant agents.Antiinflamm. Antiallergy Agents Med. Chem.20242311210.2174/011871523032211324070507175039069700
     [Google Scholar]
  15. Al-MahadeenM.M. ZahraJ.A. El-AbadelahM.M. JaberA.M. KhanfarM.A. One-pot synthesis of novel 2-oxo(2H)-spiro[benzofuran-3,3′-pyrrolines] via 1,4-dipolar cycloaddition reaction.Results Chem.2022410064310.1016/j.rechem.2022.100643
     [Google Scholar]
  16. JaberA.M. ZahraJ.A. El-AbadelahM.M. SabriS.S. SabbahD.S. Thermodynamic control synthesis of spiro[oxindole-3,3′-pyrrolines] via 1,4-dipolar cycloaddition utilizing imidazo[1,5- a ]quinoline.Z. Naturforsch. C J. Biosci.2023783-414114810.1515/znc‑2022‑008536796786
     [Google Scholar]
  17. JaberA.M. ZahraJ.A. SabriS.S. KhanfarM.A. AwwadiF.F. El-AbadelahM.M. New Trends in 1,4-Dipolar Cycloaddition Reactions. Thermodynamic Control Synthesis of Model 2′-(isoquinolin-1-yl)-spiro[oxindole-3,3′-pyrrolines].Curr. Org. Chem.202226554254910.2174/1385272826666220221141306
     [Google Scholar]
  18. JaberA.M. ZahraJ.A. El-AbadelahM.M. SabriS.S. KhanfarM.A. VoelterW. Utilization of 1-phenylimidazo[1,5- a ]quinoline as partner in 1,4-dipolar cycloaddition reactions.Z. Naturforsch. B. J. Chem. Sci.202075325926710.1515/znb‑2019‑0150
     [Google Scholar]
  19. Al-MahadeenM.M. JaberA.M. Al-NajjarB.O. Design, synthesis and biological evaluation of novel 2-hydroxy-1 H-indene-1,3(2 H)-dione derivatives as FGFR1 inhibitors.Pharmacia2024711910.3897/pharmacia.71.e122127
     [Google Scholar]
  20. Al-MahadeenM.M. JaberA.M. Al-QawasmehR.A. TahaM.O. Synthesis, evaluation, and docking study of adamantyl-1,3,4-oxadiazol hybrid compounds as CaMKIIδ kinase inhibitor.J. Chem. Res.20244831747519824126246710.1177/17475198241262467
     [Google Scholar]
  21. JaberA.M. Al-MahadeenM.M. Al-QawasmehR.A. TahaM.O. Synthesis, anticancer evaluation and docking studies of novel adamantanyl-1,3,4-oxadiazol hybrid compounds as Aurora-A kinase inhibitors.Med. Chem. Res.202332112394240410.1007/s00044‑023‑03145‑4
     [Google Scholar]
  22. MorrisG.M. HueyR. LindstromW. SannerM.F. BelewR.K. GoodsellD.S. OlsonA.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility.J. Comput. Chem.200930162785279110.1002/jcc.2125619399780
     [Google Scholar]
  23. KawaseT. NakazawaT. EguchiT. TsuzukiH. UenoY. AmanoY. SuzukiT. MoriM. YoshidaT. Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells.Oncotarget201910586111612310.18632/oncotarget.2722231692922
     [Google Scholar]
  24. MorrisG.M. GoodsellD.S. HallidayR.S. HueyR. HartW.E. BelewR.K. OlsonA.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function.J. Comput. Chem.199819141639166210.1002/(SICI)1096‑987X(19981115)19:14<1639::AID‑JCC10>3.0.CO;2‑B
     [Google Scholar]
  25. WangQ. ZhangS. GuoF. ZhangB. HuP. WangZ. Natural α-amino acids applied in the synthesis of imidazo[1,5-a]N-heterocycles under mild conditions.J. Org. Chem.20127724111611116610.1021/jo302299u23181828
     [Google Scholar]
  26. YohdaM. YamamotoY. Ruthenium–Me-BIPAM-catalyzed addition reaction of aryl-boronic acids to benzofuran-2,3-diones for the enantioselective synthesis of 3-aryl-3-hydroxybenzofuran-2-ones.Tetrahedron Asymmetry201526241430143510.1016/j.tetasy.2015.10.010
     [Google Scholar]
  27. KroppK.G. GoncalvesJ.A. AnderssonJ.T. FedorakP.M. Bacterial transformations of benzothiophene and methylbenzothiophenes.Environ. Sci. Technol.19942871348135610.1021/es00056a02522176329
     [Google Scholar]
  28. ZwanenburgD.J. ReynenW.A.P. An improved synthesis of salicylaldehydes. no influence of steric hindrance.Synthesis19761976962462510.1055/s‑1976‑24147
     [Google Scholar]
  29. ZhangY.Y. LiH. JiangX. Subba ReddyC.V. LiangH. ZhangY. CaoR. SunR.W-Y. TseM.K. QiuL. Nickel‐catalyzed decarbonylative cycloaddition of benzofuran‐2,3‐diones with alkynes to flavones.Adv. Synth. Catal.2022364352553010.1002/adsc.202101241
     [Google Scholar]
  30. SmithL.I. HolmesR.R. Action of Pyridine and Iodine upon Two o-Phenolic-1,4-diketones: 4,6,7-Trimethylcoumarandione and its 5-Hydroxy Derivative.J. Am. Chem. Soc.19517394294429710.1021/ja01153a078
     [Google Scholar]
  31. HevenerK.E. ZhaoW. BallD.M. BabaogluK. QiJ. WhiteS.W. LeeR.E. Validation of molecular docking programs for virtual screening against dihydropteroate synthase.J. Chem. Inf. Model.200949244446010.1021/ci800293n19434845
     [Google Scholar]
/content/journals/aiaamc/10.2174/0118715230343474241009112335
Loading
Discovery and Chemical Exploration of Spiro[Benzofuran-3,3'-Pyrroles] Derivatives as Innovative FLT3 Inhibitors for Targeting Acute Myeloid Leukemia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents) 24, 127 (2025); https://doi.org/10.2174/0118715230343474241009112335
/content/journals/aiaamc/10.2174/0118715230343474241009112335
/content/journals/aiaamc/10.2174/0118715230343474241009112335
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): Acute myeloid leukemia; benzofuran; cycloaddition; FMS-like tyrosine kinase 3; spiro; three-component reaction

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test